ArticleMolecular biology reports2025
Methylation status of GSTP1 and APC promoter genes as potential biomarkers for early detection and tumor aggressiveness in prostate cancer: insights from a Moroccan cohort.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- APC Promoter 1 A hypermethylation correlates with High-Risk Human Papillomavirus infection in invasive breast cancer.Molecular biology reports · 2026Article
- Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review).International journal of oncology · 2026Review
- Multi-Biofluid Approaches for cftDNA and cftRNA Biomarker Detection: Advances in Early Cancer Detection and Monitoring.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) is one of the leading causes of morbidity and mortality among men worldwide. While age, race and family history are established risk factors, their molecular underpinning remain poorly understood. Aberrant promoter methylation is a well-known mechanism for silencing tumor suppressor genes in PCa. This study evaluates the methylation status of glutathione-S-transferase-P1 (GSTP1) and adenomatous polyposis coli (APC) genes in Moroccan men with PCa, assessing their potential as biomarkers for early detection and tumor characterization.
methodsA total of 70 prostate cancer tissue samples and 50 control tissues were analyzed. Methylation specific PCR (MSP) was used to evaluate the promoter methylation status of GSTP1 and APC, The results were correlated with age, PSA levels, Gleason score, tumor stage, and life style factors.
resultsGSTP1 promoter methylation was observed in 79% of PCa cases and was significantly associated with lower Gleason scores (= 6: 64%, P = 0.006) and early T-stages tumors (T1 and T2, P = 0.002). APC methylation was found in 63% of cases and showed a significant association with higher Gleason scores (> 6: 59%, P = 0.007). Although APC methylation did not significantly correlate with pathological T-stage, it was more frequent in early stages (T1: 45%, T2: 34%). No significant associations were observed between GSTP1 or APC methylation and age, PSA levels, smoking, or alcohol consumption.
conclusionpromoter methylation of GSTP1 and APC is frequent in Moroccan prostate cancer patients. GSTP1 methylation appears to be associated with early stage disease, Whereas APC methylation is linked to tumor aggressiveness. These findings suggest the potential utility of GSTP1 and APC promoter methylation as biomarkers for prostate cancer detection and characterization, further validation with larger cohorts and gene expression analysis is needed to confirm their clinical relevance.
Indexed as
Identifiers
40663294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.